Takeda to divest four diabetes products in Japan for $1.2bn
Takeda will continue to manufacture and supply the products under the sale to Teijin Pharma
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
26 Feb 21
Takeda will continue to manufacture and supply the products under the sale to Teijin Pharma
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
25 Feb 21
PRA shareholders will own around 34% of the shares of the combined company and ICON shareholders will own…
12 Feb 21
Sandoz will obtain the global rights to GSK’s three established brands Zinnat, Zinacef and Fortum, in more than…
02 Feb 21
Horizon will benefit from Viela Bio’s Uplizna, and additional investigational drug candidates VIB4920, VIB7734, and VIB1116
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 Jan 21
The acquisition of Preventice will provide Boston Scientific with a foothold in the high-growth ambulatory electrocardiography space
20 Jan 21
Thermo Fisher will additionally pay up to $100m in cash, after reaching certain milestones post-closing of the transaction
08 Jan 21
The acquisition of AmpTec will allow Merck to strengthen its capabilities in developing and manufacturing mRNA, used in…
06 Jan 21
The acquisition of Biotheranostics will allow Hologic to leverage commercial capabilities and expertise in molecular diagnostics automation
22 Dec 20
The transaction includes Agios' marketed medicine Tibsovo and its oncology pipeline of Phase 3 and early-stage assets
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Dec 20
The acquisition will combine Philips’ in-hospital patient monitoring capabilities with BioTelemetry’s monitoring capabilities outside the hospital